News

Video

Researchers Say CAEL-101 is an Effective Amyloid Light Chain Amyloidosis Treatment

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis.

Pharmacy Times® interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis, which was presented at the 62nd American Society of Hematology Annual Meeting & Exposition.

The full conversation can be found in the video above.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Monoclonal antibodies are used to treat lung cancer. They are created in a lab and designed to target specific proteins on cancer cells, stopping them from growing and dividing.
© 2025 MJH Life Sciences

All rights reserved.